Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Kazia Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              AUSTRALIA Australia

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI North America Online

              Participation Not Confirmed

              Update your events

              Kazia Licenses Cantrixil, a Clinical-Stage, First-in-Class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

              Contact the Supplier

              Lead Product(s): Cantrixil

              Therapeutic Area: Oncology Product Name: TRE-E-002-1

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oasmia Pharmaceutical

              Deal Size: $46.0 million Upfront Cash: $4.0 million

              Deal Type: Licensing Agreement March 01, 2021

              Details:

              Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.

              Imugene

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              AUSTRALIA Australia

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI North America Online

              Participation Not Confirmed

              Update your events

              Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial

              Contact the Supplier

              Lead Product(s): PD1-Vaxx

              Therapeutic Area: Oncology Product Name: IMU-201

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 12, 2021

              Details: